People · Operator
Named in public records as an officer, director or promoter · active 2010–2010 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Protox Therapeutics Inc | — | Biotechnology | Series C | $59.7M | $12.5M | 2010 |
Jack Geltosky at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jack Geltosky on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Miller | 1 | 8 |
| Avtar Dhillon | 1 | 4 |
| Jim Heppell | 1 | 4 |
| FAHAR MERCHANT | 1 | 3 |
| John Parkinson | 1 | 3 |
| Samuel Denmeade | 1 | 1 |
| Frank Holler | 1 | 1 |
| Alexander Giaquinto | 1 | 1 |
| Tom D'Orazio | 1 | 1 |
| Nina Merchant | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.